Blog
AMD Takes NVIDIA by Storm, but Can It Keep Up the Pace?
Advanced Micro Devices (NASDAQ: AMD) has been chipping away at arch-rival NVIDIA's (NASDAQ: NVDA) discrete graphics card market share for a few years now, and did it once again in the first quarter
Why UPS is a Dividend Investor’s Dream
United Parcel Service (NYSE: UPS) operates a global network of transportation services for businesses and consumers.
While you're probably familiar with UPS in some capacity, you might be unfamiliar
4 Things Americans Want More Than Additional Stimulus Money
COVID-19 has caused unprecedented economic destruction in the U.S., and the Coronavirus Aid, Relief, and Economic Security (CARES) Act attempted to mitigate the damage to household finances by
Warren Buffett Is Making Money on This REIT, but You Probably Won't
Seritage Growth Properties (NYSE: SRG) has taken investors on a wild ride in 2020. Shares traded for around $40 in January, reflecting shareholders' optimism about the REIT's plans to redevelop
Chesapeake Energy Drilled Its Own Grave
Chesapeake Energy (NYSE: CHK) is reportedly on the brink of bankruptcy. While the recent slump in commodity prices might go down as the culprit, the company's issues run much deeper than that.
The
3 Reasons NOT to Buy Hertz Stock Now
When investors see stock from a well-known company such as Hertz (NYSE: HTZ) plunge, it's tempting to pick up shares at a low price while awaiting a rebound -- after all, buy low and sell high
Better Buy: Disney vs. Comcast
These are challenging times for big media stocks. Disney (NYSE: DIS) and Comcast (NASDAQ: CMCSA) are doing just fine with their stay-at-home businesses. Disney+ has been a hit since its November
Equinix Is a REIT You Should Know
The real estate investment trust (REIT) sector has been smashed during the COVID-19 pandemic. Mortgage REITs have seen the value of their assets fall, with their sources of funding severely
Tesla Stock Is Near $1,000: Is It a Buy, Sell, or Hold?
Shares of Tesla (NASDAQ: TSLA) have surged recently, briefly crossing $1,000 per share earlier this week. Though shares have pulled back to around $950 more recently, the stock is still notably up
Elastic Stock Looks Like a Value as Digital Transformation Demand Remains Strong
After a nearly year-long tumble culminating with the market meltdown in March 2020, shares of data analytics firm Elastic (NYSE: ESTC) are homing back in on all-time highs. Digital transformation
4 Investing Lessons From Billionaire Investor George Soros
While George Soros might not be a household name like Warren Buffett, he's one of the most successful investors in modern history. Having donated $32 billion to causes, Soros' current wealth is $8.3
Is It Too Late to Buy Boeing Stock?
Boeing (NYSE: BA) shares have been all over the map in 2020, losing half their value in March alone as part of a broader pandemic-related market sell-off. Since early May the bulls have largely been
Could Guardant Health Be a Millionaire-Maker Stock?
It has been less than two years since Guardant Health's (NASDAQ: GH) IPO in October 2018. Since that time, shares of the cancer diagnostic company have returned 298%, compared to the S&P 500's 2.47%
Lost Value in Your Retirement Plan and Worried It Won’t Recover? Social Security Can Help
The COVID-19 crisis hasn't just had a health-related impact; it's also caused a world of financial hurt. Not only did U.S. unemployment levels reach record highs in both April and May, but back in
3 Incredibly Cheap Bank Stocks
Despite this past week's pullback, bank stocks have been on a nice run as of late, buoyed by the gradual reopening of state economies and people getting back to work. In the first week of June
Is Bicycle Therapeutics Stock a Buy?
In 2018, the founder of Bicycle Therapeutics (NASDAQ: BCYC), Sir Gregory Winter, was awarded the Nobel Prize in chemistry for his work in developing phage display (use of viruses that infect
If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now
If you had invested $1,000 in shares of mid-cap biotech company Fate Therapeutics (NASDAQ: FATE) when it IPO'd, you would have close to $4,823.33 as of markets' close on June 11. That's an
3 Pot Stocks With Less Than $100 Million in Cash
Cash is at a premium in the cannabis industry these days. For investors, it's an important consideration when investing in a pot stock because those without much cash on hand could be in for a rough
Better Coronavirus Stock: OPKO Health or Emergent Biosolutions?
Many companies have shifted into high gear to address the multiple needs related to the COVID-19 pandemic. Two at the forefront of these efforts are OPKO Health (NASDAQ: OPK) and Emergent
There Won't Be Another COVID-19 Lockdown. Here Are 3 Reasons Why
Unbelievably, stocks have recouped just about all of their losses from the coronavirus crash.
The NASDAQ reached an all-time high, topping 10,000 earlier this week, and until Thursday's plunge, the
Why Mark Cuban Compares Today's Market to the Dot-Com Bubble
Today's stock market is starting to feel like the dot-com bubble, according to billionaire investor and Shark Tank star Mark Cuban.
In an interview with Real Vision, Cuban said that it wasn't just
3 Reasons Americans May Not Get a Second Round of Stimulus Checks
Tens of millions of Americans have lost their jobs as the COVID-19 pandemic has spread across the country, and countless small businesses continue to struggle. And while a modicum of relief has come
1 Investing Move That Can Protect Your Retirement Savings
Investing in the stock market can be daunting, especially during economic downturns. The stock market can experience extreme volatility at times, which can be concerning when your life savings are
Could This Recent IPO Biotech Become the Next Moderna?
So far in 2020, no biotech has come close to pulling off a huge initial public offering (IPO) even close to what Moderna (NASDAQ: MRNA) did in late 2018. That's no knock against any of the biotechs
3 Stocks for Starting Your Portfolio in 2020
When starting a portfolio from scratch, simplicity is key. Rather than trying to find the small-cap diamond in the rough, new investors are better served by focusing on a more straightforward


